跳至主要内容
临床试验/NCT06956131
NCT06956131进行中(未招募)不适用

Metabolite Changes Following Consumption Of Different Protein Drinks In Singapore Older Adults

National University of Singapore1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2025年5月20日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
32
试验地点
1
主要终点
Changes in metabolites found in plasma (plasma metabolomics)

研究概览

简要总结

The study aims to investigate the acute effects of different protein sources (i.e., casein, whey, soy) on metabolomic profiles (e.g., amino acids in the blood), along with other outcomes such as cognitive function, mood, and appetite. While the study does not directly aim to prevent, prognosticate, diagnose, or alleviate any disease, it may provide insights that could inform dietary recommendations and support disease prevention efforts in older adults.

详细描述

This study will be a double-blind, randomised, placebo-controlled trial using a crossover study design. 25 older adults (aged 60 to 80) will be recruited and assigned to consume 4 different test drinks in a random order on 4 different visits. This study aims to investigate whether higher protein consumption of different sources will influence postprandial plasma and urinary metabolomic profiles, cognition, mood and appetite. The study will comprise 1 screening visit and 4 test visits separated separated by a minimum washout period of >7 days

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
60 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •English-literate and able to give informed consent
  • •Adults 60 to 80 years old (inclusive)
  • •(If applicable) Postmenopausal
  • •BMI of 18·5 to 30 kg/m2 (inclusive)

排除标准

  • •Currently participating in another clinical study that involves altering the regular diet and/or involves consuming a dietary supplement or investigated food product as an intervention
  • •Weight change >3 kg in the past 3 months
  • •Exercising vigorously over the past 3 months (i.e., engaging in high-intensity exercises for more than 3 hours a week, where high-intensity exercises leave one out of breath and unable to talk or sing during the workout)
  • •Current smokers or have quit smoking for less than 5 years
  • •Drinking >2 alcoholic drinks per day (i.e., one drink is defined as either 150 ml of wine, 340 ml of beer/cider or 45 ml of distilled spirit)
  • •If drinking ≤2 alcoholic drinks per day, not willing to stop consumption of alcoholic beverages two days before and on the day of the test visits (total 12 days)
  • •Not willing to stop consumption of caffeinated beverages 10 to 12 hours before and on the day of the test visits (total 4 days)
  • •Taking supplements containing omega-3, magnesium, gamma-aminobutyric acid (GABA), L-theanine, melatonin and/or 5-hydroxytryptophan for the past 3 months, and not willing to discontinue usage 3 months before and during the study duration
  • •Currently on a specialised diet (e.g., vegetarian, vegan, weight loss diet)
  • •Had serious food allergies in the past, or having intolerance, sensitivities or allergies to any of the following: milk/dairy products (e.g., casein, whey), starch/starch-derived products (e.g., rice, corn, wheat, potato), soy/soy-derived products, gluten, eggs, nuts, peanuts, fish and crustaceans.
  • •Disease or impairment of the kidney and/or liver
  • •Currently diagnosed with diabetes, sleep disorders, gastrointestinal issues (e.g., lactose intolerance, irritable bowel syndrome), gout and/or G6PD deficiency
  • •History of diseases known to affect the central nervous system (e.g., heart disease, stroke, migraine headaches, multiple sclerosis, Parkinson's disease, mental illnesses)
  • •Taking antibiotics 2 weeks prior to study participation
  • •Taking medication known to interfere with cognitive function and mental wellbeing (e.g., benzodiazepines, antidepressants, other central nervous agents)
  • •Taking anti-hypertensive or cholesterol-lowering drugs for less than 3 years unless medically declared by an official doctor to be in stable condition
  • •Poor peripheral venous access based on past experiences with blood drawing

研究组 & 干预措施

Casein Protein Drink

Experimental

30 g protein equivalent of casein protein isolate dissolved in ~250 mL of water

干预措施: Casein Protein Isolate Drink (Dietary Supplement)

Whey Protein Drink

Experimental

30 g protein equivalent of whey protein isolate dissolved in ~250 mL of water

干预措施: Whey Protein Isolate Drink (Dietary Supplement)

Soy Protein Drink

Experimental

30 g protein equivalent of soy protein isolate dissolved in ~250 mL of water

干预措施: Soy Protein Isolate Drink (Dietary Supplement)

Maltodextrin Drink

Placebo Comparator

30 g carbohydrate equivalent of maltodextrin powder dissolved in ~250 mL of water

干预措施: Maltodextrin Drink (Dietary Supplement)

结局指标

主要结局

Changes in metabolites found in plasma (plasma metabolomics)

时间窗: Baseline, 15, 30, 60, 90, 120, 180, 240, 300 minutes

Untargeted metabolomics profiling of plasma will be conducted using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS)

Changes in metabolites found in urine (urinary metabolomics)

时间窗: Baseline, 60, 120, 180, 240, 300 minutes

Untargeted metabolomics profiling of urine will be conducted using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS)

次要结局

  • Cognitive Function(Baseline, 15, 60, 120, 180, 240, 300 minutes)
  • Mood(Baseline, 15, 60, 120, 180, 240, 300 minutes)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jung Eun Kim

Assistant Professor

National University of Singapore

研究点 (1)

Loading locations...

相似试验

Metabolite Changes Following Consumption Of... | 临床试验